Use of generic anti-epilepsy drugs in France: Survey of neurologists and review of the literature;Utilisation des médicaments génériques des anti-épileptiques en France: Résultats d'une enquête auprès des neurologues et revue de la littérature

Revue Neurologique

Volumn 163, Issue 4, 2007, Pages 455-461

  Biraben, A ^a   De Toffol, B ^b   Semah, F ^c   Rouaud, T ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^b CHU BRETONNEAU   (France)

^c CENTRE HOSPITALIER SAINTE ANNE   (France)

Author keywords

Antiepileptic drug; Generic

Indexed keywords

ANTICONVULSIVE AGENT; GENERIC DRUG;

ADVERSE OUTCOME; ARTICLE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG USE; EPILEPSY; FRANCE; HOSPITAL PERSONNEL; HUMAN; MEDICAL SPECIALIST; NEUROLOGY; PATIENT SATISFACTION; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIVATE PRACTICE; QUESTIONNAIRE; SEIZURE; TELEMEDICINE; DRUG UTILIZATION; PHARMACIST;

ANTICONVULSANTS; DRUG UTILIZATION; DRUGS, GENERIC; EPILEPSY; FRANCE; NEUROLOGY; PHARMACISTS; QUESTIONNAIRES;

EID: 34250021143     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0035-3787(07)90421-x     Document Type: Article

References (27)

1. Assessment: generic substitution for antiepileptic medication. (1990). Report of the Therapeutics and Technology Assessment Subcomittee of the American Academy of Neurology. Neurology, 40 (11): 1641-3 [No authors listed].
2. BURKHARDT RT, LEPPIK IE, BLESI K, SCOTT S, GAPANY SR, CLOYD JC. (2004). Lower phenytoin serum levels in persons switched from brand to generic phenytoin. Neurology, 63: 1494-1496.
3. CRAWFORD P, HALL WW, CHAPPELL B, COLLINGS J, STEWART A. (1996). Generic prescribing for epilepsy: is it safe? Seizure, 5: 1-5.
4. DHANARAJ M, JAYAVELU A. (2004). Non-equivalence of bioavailability between generic and branded form of sodium valproate. Neurol India, 52: 398.
5. GILMAN JT, ALVAREZ LA, DUCHOWNY M. (1993). Carbamazepine toxicity resulting from generic substitution. Neurology, 43: 2696-2697.
6. GOODWIN M. (2005). The importance of brand continuity in epilepsy drugs. Nurs Times, 101: 26.
7. HASKINS LS, TOMASZEWSKI KJ, CRAWFORD P. (2005). Patient and physician reactions to generic antiepileptic substitution in the treatment of epilepsy. Epilepsy Behav, 7: 98-105.
8. JOBST BC, HOLMES GL. (2004). Prescribing Antiepileptic Drugs. Should patients be switched on the basis of cost? CNS Drugs, 18: 617-628.
9. KRAMER G, DENNIG D, SCHMIDT D et al. (2005). Generics in Antiepileptic Drug Therapy: What has to be considered? Akt Neurol, 32: 275-278.
10. KOCH G, ALLEN JP. (1978). Untoward effects of generic carbamazepine therapy. Arch Neurol, 44: 578-579.
11. LAM YW, ERESHEFSKY L, TONEY GB, GONZALES C. (2001). Branded versus generic clozapine: bioavailability comparison and interchangeability issues. J Clin Psychiatry, 62: 18-22.
12. MACDONALD JT. (1987). Breakthrough seizure following substitution of Depakene capsules (Abbott) with a generic product. Neurology, 37: 1885.
13. MOFSEN R, BALTER J. (2001). Case report of the reemergence of psychotic symptoms after conversion from brand-name clozapine to a generic formulation. Clin Ther, 23: 1720-1731.
14. National Institute for Clinical Excellence Guideline. (2004). The epilepsies: diagnosis and management of the epilepsies in adults in primary and secondary care. Clinical Guideline, 20.
15. OLES KS, PENRY JK, SMITH LD, ANDERSON RL, DEAN JC, RIELA AR. (1992). Therapeutic bioequivalency study brand name versus generic carbamazepine. Neurology, 42: 1147-1153.
16. OLLING M, MESINGA TT, BARENDS DM, GROEN C, LAKE OA, MEULENBELT J. (1999). Bioavailability of carbamazepine from four different products and the occurrence of side effects. Drug Dispos, 20: 19-28
17. REVANKAR SN, DESAI ND, BHATT AD et al. (1999). Comparison of absorption rate and bioavailability of two brands of carbamazepine. J Assoc Physicians India, 47: 699-702.
18. ROSENBAUM DH, ROWAN AJ, TUCHMAN L, FRENCH JA. (1994). Comparative bioavailability of a generic phenytoin and Dilantin. Epilepsia, 35: 656-660.
19. SACHDEO RC, BELENDIUK G. (1987). Generic versus branded carbamazepine. Lancet, 20: 1432.
20. SHERWOOD-BROWN E, SHELLHORN E, SUPPES T. (1998) Gastrointestinal side effects after switch to generic valproic acid. Pharmacopsychiatry, 31: 114.
21. SILPAKIT O, AMORNPICHETKOON M, KAOJARERN S. (1997). Comparative study of bioavailability and clinical efficacy of carbamazepine in epileptic patients. Ann Pharmacother, 31: 548-552.
22. VADNEY VJ, KRAUSHAAR KW. (1997). Effects of switching from Depakene to generic valproic acid on individuals with mental retardation. Ment Retard, 35: 468-472.
23. WELTY TE, PICKERING PR, HALE BC, ARAZI R. (1992). Loss of seizure control associated with generic substitution of carbamazepine. Ann Pharmacoter, 26: 775-777.
24. WILDER BJ, LEPPICK I, HIETPAS TJ, CLOYD JC, RANDINITIS EJ, COOK J. (2001). Effects of food on absorption of Dilantin Kapseal and Mylan extended phenytoin sodium capsules. Neurology, 58: 582-589.
25. WILNER AN. (2004). Therapeutic equivalency of generic antiepileptic drugs: results of a survey. Epilepsy Behav, 5: 995-998.
26. WOLF P, MAY T et al. (1992). Steady state concentrations and diurnal fluctuations of carbamazepine in patients after different slow release formulations. Arzneimittelforschung, 42: 284-288
27. YU BP, CHONG YS, MAGUIRE GA. (2004). Is generic fluoxetine effective? J Affect Disord, 81: 185-186.